Lixisenatide
Lixisenatide is an FDA-approved GLP-1 receptor agonist. Lixisenatide is an exendin-4 analog carrying a C-terminal polylysine extension that increases its affinity for the GLP-1 receptor and its resistance to enzymatic degradation. Its short duration of action produces a pronounced effect on gastric emptying, which is the main driver of its comparatively larger reduction in post-prandial glucose relative to fasting glucose.
For research use only.
Key Facts
- CAS
- 320367-13-3
- Molecular Weight (MW)
- 4858 g/mol
- Half-life
- —
- FDA status
- Approved
- Administration Route
- subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Once-daily short-acting GLP-1 receptor agonist derived from exendin-4, approved for glycaemic control in adults with type 2 diabetes and also formulated in fixed-ratio combination with insulin glargine.
Peptide Library's Lixisenatide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- subcutaneous
- Reconstitution Guide
- —
Sequence & molecular data
| Amino acid sequence | His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys |
|---|---|
| Molecular formula | C215H347N61O65S |
| Molecular weight | 4858 g/mol |
| CAS number | 320367-13-3 |
| PubChem CID | 90472060 |
| FDA UNII | 74O62BB01U |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Lixisenatide is an exendin-4 analog carrying a C-terminal polylysine extension that increases its affinity for the GLP-1 receptor and its resistance to enzymatic degradation. Its short duration of action produces a pronounced effect on gastric emptying, which is the main driver of its comparatively larger reduction in post-prandial glucose relative to fasting glucose.
Studies
- Trial of Lixisenatide in Early Parkinson's Disease
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- Lixisenatide: first global approval
Regulatory & research status
Lixisenatide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Lixisenatide: frequently asked questions
What is Lixisenatide?
Once-daily short-acting GLP-1 receptor agonist derived from exendin-4, approved for glycaemic control in adults with type 2 diabetes and also formulated in fixed-ratio combination with insulin glargine.
How does Lixisenatide work?
Lixisenatide is an exendin-4 analog carrying a C-terminal polylysine extension that increases its affinity for the GLP-1 receptor and its resistance to enzymatic degradation. Its short duration of action produces a pronounced effect on gastric emptying, which is the main driver of its comparatively larger reduction in post-prandial glucose relative to fasting glucose.
Is Lixisenatide FDA approved?
Yes. Lixisenatide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What is the amino acid sequence of Lixisenatide?
Lixisenatide has the sequence His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys, giving a chain of 44 amino acids. Its molecular formula is C215H347N61O65S.
What peptides are similar to Lixisenatide?
Compounds most often compared with Lixisenatide include Semaglutide, Tirzepatide, Retatrutide and Liraglutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Trial of Lixisenatide in Early Parkinson's Disease — N Engl J Med, 2024External reference
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome — N Engl J Med, 2015External reference
- Adverse drug reactions of GLP-1 agonists: A systematic review of case reports — Diabetes Metab Syndr, 2022External reference
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis — Lancet Diabetes Endocrinol, 2018External reference
- Lixisenatide: first global approval — Drugs, 2013External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Lixisenatide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Lixisenatide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →